334117
Transition to ICD-10: Implications for Suicide Prevention
Tuesday, November 3, 2015
Chuck Lunati,
Resource and Force Management, Calibre Systems Inc, Alexandria, VA
Psychiatric hospitals use the DSM coding system, however all other clinicians code for patient visits using the International Classification of Diseases (ICD) system. While the rest of the world is using ICD version 10, the United States is still using ICD version 9, which has been in use since the 1970s. Congress and the Centers for Medicare and Medicaid Services (CMS) have set the deadline for transition to ICD-10 as October 1, 2015. This is extremely relevant to suicide prevention, both from the perspective of a clinician as well as for research purposes. While mortality data has been coded in ICD-10 in the United States since 1999, this will be the first time suicide attempts and ideation will be coded in a manner that gets reimbursed as a diagnosis and can be used to determine the number of suicide attempts in the country. Once data on suicide attempts are available, programs may be developed and evaluated using number of attempts as the measure of effectiveness. This session will talk about this upcoming change and implications for suicide prevention.
Learning Areas:
Administration, management, leadership
Biostatistics, economics
Clinical medicine applied in public health
Provision of health care to the public
Public health administration or related administration
Social and behavioral sciences
Learning Objectives:
Define ICD-10 codes that would be of relevance for suicide attempts and ideation.
Discuss documentation necessary for effective coding
Analyze implications for getting data on suicide attempts and ideation for research and to inform prevention efforts
Keyword(s): Behavioral Research, Statistics
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I have conducted the research and analysis that led to the findings that will be presented
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
